Literature DB >> 14763373

Asthma epidemiology: risk factors, case finding, and the role of asthma coalitions.

Sharon A Petronella1, Kathleen Conboy-Ellis.   

Abstract

Asthma has no cure, and given that clinicians still do not understand what causes it in the first place, it is not preventable. With implementation of environmental control measures to minimize exposure to allergens and irritants, appropriate pharmacologic therapy, and patient and health care provider education, the disease can be managed successfully. Health care access and appropriate case management are essential components of any plan to address asthma as a public health problem. Asthma is now one of the most important diseases of childhood in developed countries. In the International Study of Asthma and Allergies in Childhood (ISAAC) study, the highest asthma prevalence was observed in westernized English-speaking countries (e.g., the United Kingdom, Australia, and New Zealand), with much lower prevalence rates in Eastern Europe, India, China, other countries in Asia, and Africa [18]. This observation has led to the belief that the rapid increases in asthma prevalence are more likely to be attributable to environmental than genetic factors. The rising prevalence in the United States and worldwide seems to be correlated with modern industrialization, suggesting that changes in the ambient environment may contribute to this increase in morbidity and mortality. Indoor factors that have been suggested to influence asthma pathogenesis include allergy to house dust mite and cockroaches, poor heating and ventilation, and exposure to cigarette smoke and other irritants. Scientific evaluation of the links between indoor and outdoor air pollution and asthma is incomplete, however. Much work remains to be done in defining the environmental factors that may cause asthma and that may trigger asthma exacerbations in individuals with the disease. Until then, clinicians must focus on developing a hard-hitting, comprehensive, interdisciplinary asthma program and work toward its successful and broad-based implementation. It is the only way to win the "war against asthma."

Entities:  

Mesh:

Year:  2003        PMID: 14763373     DOI: 10.1016/s0029-6465(03)00099-9

Source DB:  PubMed          Journal:  Nurs Clin North Am        ISSN: 0029-6465            Impact factor:   1.208


  5 in total

1.  Neuroimmune semaphorin 4A as a drug and drug target for asthma.

Authors:  G Mogie; K Shanks; E H Nkyimbeng-Takwi; E Smith; E Davila; M M Lipsky; L J DeTolla; A D Keegan; S P Chapoval
Journal:  Int Immunopharmacol       Date:  2013-08-28       Impact factor: 4.932

2.  Age-period-cohort analysis of asthma prevalence among school children.

Authors:  Etsuji Okamoto; Eiichi Hata; Masako Kobayashi; Kenji Hayashi
Journal:  Environ Health Prev Med       Date:  2007-05       Impact factor: 3.674

3.  IL‑27 suppresses airway inflammation, hyperresponsiveness and remodeling via the STAT1 and STAT3 pathways in mice with allergic asthma.

Authors:  Degan Lu; Jiameng Lu; Xiaoqing Ji; Yanbo Ji; Zewen Zhang; Haiying Peng; Fei Sun; Caiqing Zhang
Journal:  Int J Mol Med       Date:  2020-05-29       Impact factor: 4.101

4.  Prevalence, socio-demographic and environmental determinants of asthma in 4621 Ghanaian adults: Evidence from Wave 2 of the World Health Organization's study on global AGEing and adult health.

Authors:  Justice Moses K Aheto; Emilia A Udofia; Eugene Kallson; George Mensah; Minicuci Nadia; Naidoo Nirmala; Somnath Chatterji; Paul Kowal; Richard Biritwum; Alfred E Yawson
Journal:  PLoS One       Date:  2020-12-09       Impact factor: 3.240

5.  Short-term effects of fine particulate matter on non-accidental and circulatory diseases mortality: A time series study among the elder in Changchun.

Authors:  Yangming Qu; Yang Pan; Huikun Niu; Yinghua He; Meiqi Li; Lu Li; Jianwei Liu; Bo Li
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.